Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

2017-10-01
Price :
Published : Oct-2017
No. of Pages : 567
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 12
1.2 List of Figures 20
2 Introduction 21
2.1 Lung Cancer Diagnostic Tests Overview 21
3 Products under Development 22
3.1 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 22
3.2 Lung Cancer Diagnostic Tests - Pipeline Products by Territory 23
3.3 Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 24
3.4 Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 25
3.5 Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 26
4 Lung Cancer Diagnostic Tests - Pipeline Products under Development by Companies 27
4.1 Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 27
4.2 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 32
5 Lung Cancer Diagnostic Tests Companies and Product Overview 37
5.1 A&G Pharmaceutical Inc Company Overview 37
5.2 Abbott Diagnostics Company Overview 39
5.3 Abcodia Ltd Company Overview 44
5.4 Aberystwyth University Company Overview 46
5.5 Acobiom Company Overview 47
5.6 Advanced Marker Discovery SL Company Overview 49
5.7 Advpharma Inc Company Overview 51
5.8 AIT Austrian Institute of Technology GmbH Company Overview 52
5.9 Almac Diagnostics Ltd Company Overview 53
5.10 Arizona State University Company Overview 55
5.11 Armune BioScience Inc Company Overview 56
5.12 Aurelium BioPharma Inc. Company Overview 57
5.13 Avant Diagnostics, Inc. Company Overview 58
5.14 BARD1 Life Sciences Ltd Company Overview 59
5.15 Biocept Inc Company Overview 60
5.16 BioChain Institute Inc Company Overview 62
5.17 Biodesix Inc Company Overview 65
5.18 Biological Dynamics, Inc. Company Overview 68
5.19 BioMark Diagnostics Inc. Company Overview 69
5.20 BioMarker Strategies LLC Company Overview 72
5.21 BioNTech AG Company Overview 74
5.22 BioSystems International Company Overview 75
5.23 Cancer Genetics Inc Company Overview 76
5.24 Cancer Research Technology Ltd Company Overview 77
5.25 Cangen Biotechnologies Inc (Inactive) Company Overview 78
5.26 CDI Laboratories Inc Company Overview 79
5.27 Cellanyx Diagnostics, Inc. Company Overview 80
5.28 CellMax Life Company Overview 81
5.29 CeMines, Inc. (Inactive) Company Overview 82
5.30 Cepheid Company Overview 83
5.31 Ceres Nanosciences Inc Company Overview 85
5.32 Cernostics Inc. Company Overview 86
5.33 ChemImage Corp Company Overview 87
5.34 Children's Hospital Boston Company Overview 88
5.35 Clarient Inc Company Overview 89
5.36 Courtagen Life Sciences Inc Company Overview 91
5.37 DiagnoCure Inc. (Inactive) Company Overview 92
5.38 EDP Biotech Corporation Company Overview 93
5.39 Emory University Company Overview 94
5.40 Epic Sciences Inc Company Overview 95
5.41 Epigenomics AG Company Overview 96
5.42 Eventus Diagnostics Inc (Inactive) Company Overview 98
5.43 Exact Sciences Corp Company Overview 99
5.44 Exiqon A/S Company Overview 100
5.45 Exosomics Siena SpA Company Overview 101
5.46 Fahy Gurteen UK Ltd Company Overview 102
5.47 Fina Biotech SL Company Overview 103
5.48 French National Institute of Health and Medical Research Company Overview 104
5.49 Fresh Medical Laboratories Inc Company Overview 105
5.50 Gene Express, Inc. (Inactive) Company Overview 108
5.51 GeneCentric Diagnostics, Inc. Company Overview 110
5.52 Global Discovery Biosciences Corporation Company Overview 111
5.53 GlycoZym Company Overview 112
5.54 HalioDx SAS Company Overview 113
5.55 ImmunoCellular Therapeutics Ltd Company Overview 114
5.56 Imperial College London Company Overview 115
5.57 Insight Genetics Inc Company Overview 116
5.58 InterGenetics Inc Company Overview 119
5.59 IV Diagnostics, Inc. Company Overview 120
5.60 Janssen Biotech Inc Company Overview 121
5.61 Laboratorios SALVAT SA Company Overview 122
5.62 Louisville Bioscience, Inc. Company Overview 123
5.63 Mayo Clinic US Company Overview 124
5.64 MDNA Life Sciences Inc Company Overview 125
5.65 MDxHealth SA Company Overview 126
5.66 MEDITE Cancer Diagnostics Inc Company Overview 127
5.67 Memory Dx LLC Company Overview 128
5.68 Merrimack Pharmaceuticals Inc Company Overview 129
5.69 Metabolon Inc Company Overview 130
5.70 Metanomics Health GmbH Company Overview 131
5.71 MetaStat Inc Company Overview 132
5.72 Milagen Inc Company Overview 133
5.73 MiRXES Pte Ltd Company Overview 134
5.74 Nanocytomics LLC Company Overview 135
5.75 Nanopore Diagnostics, LLC Company Overview 138
5.76 NEOMICS Co Ltd Company Overview 139
5.77 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 140
5.78 Oncimmune (USA) LLC Company Overview 141
5.79 OncoCyte Corp Company Overview 142
5.80 Oncolome Diagnostics Inc (Inactive) Company Overview 147
5.81 Onconome, Inc. (Inactive) Company Overview 148
5.82 OncoStem Diagnostics Pvt. Ltd Company Overview 149
5.83 On-Q-ity, Inc. (Inactive) Company Overview 150
5.84 OPKO Health Inc Company Overview 151
5.85 Orion Genomics LLC Company Overview 152
5.86 OTraces Inc. Company Overview 153
5.87 Oxford Gene Technology Ltd Company Overview 154
5.88 PeriRx LLC Company Overview 155
5.89 PleX Diagnostics Inc (Inactive) Company Overview 158
5.90 Precision Biologics Inc Company Overview 159
5.91 PreMD Inc (Inactive) Company Overview 160
5.92 Proplex Technologies Llc Company Overview 161
5.93 Proteome Sciences Plc Company Overview 162
5.94 Proteomika Company Overview 163
5.95 Provista Diagnostics Inc Company Overview 164
5.96 Quest Diagnostics Inc Company Overview 165
5.97 Research Center Borstel Company Overview 167
5.98 Roche Diagnostics International Ltd Company Overview 168
5.99 Rosetta Genomics Ltd Company Overview 173
5.100 Roswell Park Cancer Institute Company Overview 174
5.101 Savicell Diagnostic Ltd. Company Overview 175
5.102 Siemens Healthcare GmbH Company Overview 176
5.103 Sienna Cancer Diagnostics Ltd Company Overview 178
5.104 Simon Fraser University Company Overview 179
5.105 Sividon Diagnostics GmbH Company Overview 180
5.106 SomaLogic Inc Company Overview 181
5.107 Southern Illinois University Carbondale Company Overview 182
5.108 Syndax Pharmaceuticals Inc Company Overview 183
5.109 Sysmex Corp Company Overview 184
5.110 The Wistar Institute Company Overview 185
5.111 Transgene SA Company Overview 186
5.112 TransGenic Inc Company Overview 187
5.113 Treos Bio Inc Company Overview 188
5.114 Trinity College Dublin Company Overview 189
5.115 Universal Diagnostics SL Company Overview 190
5.116 University of California San Francisco Company Overview 191
5.117 University of Chicago Company Overview 192
5.118 University of Colorado Company Overview 194
5.119 University of Maryland Company Overview 195
5.120 University of Queensland Company Overview 196
5.121 University of South Florida Company Overview 197
5.122 University of Strathclyde Company Overview 198
5.123 US Biomarkers Inc Company Overview 199
5.124 Vanderbilt University Company Overview 200
5.125 Ventana Medical Systems Inc Company Overview 201
5.126 Viomics Inc. Company Overview 202
5.127 VisionGate, Inc. Company Overview 203
5.128 Vitatex Inc. Company Overview 204
5.129 VolitionRX Ltd Company Overview 205
5.130 Weizmann Institute of Science Company Overview 208
5.131 XEPTAGEN SpA Company Overview 209
5.132 Zetiq Technologies Ltd Company Overview 211
6 Lung Cancer Diagnostic Tests - Recent Developments 212
6.1 Sep 07, 2017: OncoCyte Receives CLIA Certification for its Cancer Diagnostics Laboratory 212
6.2 Sep 06, 2017: Simple blood test opens door to new treatments for lung cancer patients 212
6.3 Sep 06, 2017: MDxHealth Prepares for Growth with Executive Team Expansion 213
6.4 Sep 06, 2017: Sandra Cole Appointed Vice President and Chief Compliance Officer for OPKO's BioReference Laboratories 214
6.5 Sep 05, 2017: Seasoned Diagnostics Sales Executive Joins OncoCyte to Drive Commercialization and Future Sales Initiatives of DetermaVu, the Companys Novel Liquid Biopsy Lung Cancer Diagnostic 214
6.6 Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 215
6.7 Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 215
6.8 Aug 31, 2017: MDxHealth Announces First Half 2017 Financial Results 216
6.9 Aug 31, 2017: MPI publishes Half-year Report for the first half of 2017 219
6.10 Aug 31, 2017: Sienna Cancer Diagnostics: Appendix 4E & 2017 Financial Report Release 220
6.11 Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 221
6.12 Aug 29, 2017: Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs 221
6.13 Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 222
6.14 Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 222
6.15 Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy 223
6.16 Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 224
6.17 Aug 21, 2017: 20/20's Lung Cancer Detection Technology Launches in China 225
6.18 Aug 21, 2017: Unique test to help detect lung cancer early 225
6.19 Aug 17, 2017: Victoria Laughman Named Executive Vice President of Sales for OPKO's BioReference Laboratories 226
6.20 Aug 15, 2017: Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results 227
6.21 Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 227
6.22 Aug 14, 2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results 229
6.23 Aug 10, 2017: Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update 230
6.24 Aug 10, 2017: Biocept Reports Second Quarter 2017 Financial Results 232
6.25 Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 235
6.26 Aug 08, 2017: Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression in Lung Cancer 236
6.27 Aug 08, 2017: HTG Molecular Diagnostics Reports Second Quarter 2017 Results 237
6.28 Aug 07, 2017: BARD1 Life Sciences: Australian Patent Issued In Core Patent Family 237
6.29 Aug 07, 2017: OncoCyte Latest Lung Cancer Diagnostic Test Data Accepted for Slide Presentation at CHEST 2017 Annual Meeting 238
6.30 Aug 07, 2017: MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion 238
6.31 Aug 03, 2017: Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update 239
6.32 Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 240
6.33 Aug 01, 2017: Proteome Sciences: Directorate changes 244
6.34 Aug 01, 2017: llumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 245
6.35 Aug 01, 2017: Illumina Reports Strong Financial Results for Second Quarter of Fiscal Year 2017 246
6.36 Jul 31, 2017: Veracyte Announces Second Quarter 2017 Financial Results 247
6.37 Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 248
6.38 Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 250
6.39 Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 254
6.40 Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 256
6.41 Jul 25, 2017: Roche gains CE label expansion for companion diagnostic to identify ALK-positive non-small cell lung cancer patients 262
6.42 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 263
6.43 Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 264
6.44 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook 264
6.45 Jul 25, 2017: Cologuard revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 264
6.46 Jul 24, 2017: Oncocyte Analytical Validation Study of Its Lung Cancer Diagnostic Test Confirms Previously Published Results 265
6.47 Jul 21, 2017: GSK announces Board and Committee changes 267
6.48 Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 267
6.49 Jul 18, 2017: LabCorp's William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 273
6.50 Jul 18, 2017: Hans E. Bishop to Join Agilent's Board of Directors 274
6.51 Jul 18, 2017: Lew Titterton re-joins ITUS Board of Directors 274
6.52 Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 275
6.53 Jul 13, 2017: New ACRF Research Centre Targets Early Detection Of Lung Cancer 275
6.54 Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 276
6.55 Jul 10, 2017: Lung Cancer: VeriStrat Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy 277
6.56 Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 278
6.57 Jul 06, 2017: Epigenomics issues change in guidance for financial year 2017 278
6.58 Jul 03, 2017: Premaitha Health Litigation Update 278
7 Appendix 561
7.1 Methodology 561
7.2 About GlobalData 564
7.3 Contact Us 564
7.4 Disclaimer 564

1.1 List of Tables
Table 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 25
Table 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 26
Table 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 27
Table 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 28
Table 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 29
Table 6: Lung Cancer Companies - Pipeline Products by Stage of Development 30
Table 7: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 35
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 40
Table 9: Onco 88 - Lung Cancer - Product Status 40
Table 10: Onco 88 - Lung Cancer - Product Description 40
Table 11: OncoStain 88 - Lung Cancer - Product Status 41
Table 12: OncoStain 88 - Lung Cancer - Product Description 41
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 42
Table 14: ARCHITECT c4000 System - NSE Assay - Product Status 42
Table 15: ARCHITECT c4000 System - NSE Assay - Product Description 42
Table 16: ARCHITECT c8000 System - NSE Assay - Product Status 43
Table 17: ARCHITECT c8000 System - NSE Assay - Product Description 43
Table 18: ARCHITECT ci4100 Integrated System - NSE Assay - Product Status 43
Table 19: ARCHITECT ci4100 Integrated System - NSE Assay - Product Description 44
Table 20: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status 44
Table 21: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description 44
Table 22: ARCHITECT i1000SR System - NSE Assay - Product Status 45
Table 23: ARCHITECT i1000SR System - NSE Assay - Product Description 45
Table 24: ARCHITECT i2000SR - Neuron-Specific Enolase Assay - Product Status 45
Table 25: ARCHITECT i2000SR - Neuron-Specific Enolase Assay - Product Description 46
Table 26: PRAME Antigen Lung Cancer Assay - Product Status 46
Table 27: PRAME Antigen Lung Cancer Assay - Product Description 46
Table 28: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 47
Table 29: Diagnostic Assay - Lung Cancer - Product Status 47
Table 30: Diagnostic Assay - Lung Cancer - Product Description 47
Table 31: MCM Test - Lung Cancer - Product Status 48
Table 32: MCM Test - Lung Cancer - Product Description 48
Table 33: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview 49
Table 34: Diagnostic Biomarker Test - Lung Cancer - Product Status 49
Table 35: Diagnostic Biomarker Test - Lung Cancer - Product Description 49
Table 36: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 50
Table 37: Companion Diagnostic Test - Lung Cancer - Product Status 50
Table 38: Companion Diagnostic Test - Lung Cancer - Product Description 50
Table 39: Diagnostic/Prognostic Assay - Lung Cancer - Product Status 51
Table 40: Diagnostic/Prognostic Assay - Lung Cancer - Product Description 51
Table 41: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 52
Table 42: Predictive Diagnostic Test - Lung Cancer - Product Status 52
Table 43: Predictive Diagnostic Test - Lung Cancer - Product Description 52
Table 44: Prognostic Test - Lung Cancer - Product Status 53
Table 45: Prognostic Test - Lung Cancer - Product Description 53
Table 46: Advpharma Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 47: Lung Cancer Prognostic Assay - Product Status 54
Table 48: Lung Cancer Prognostic Assay - Product Description 54
Table 49: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 55
Table 50: Biomarker Assay - Lung Cancer - Product Status 55
Table 51: Biomarker Assay - Lung Cancer - Product Description 55
Table 52: Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
Table 53: Prognostic Test - Early Stage Lung Cancer - Product Status 56
Table 54: Prognostic Test - Early Stage Lung Cancer - Product Description 56
Table 55: Prognostic Test - NSCLC - Product Status 57
Table 56: Prognostic Test - NSCLC - Product Description 57
Table 57: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 58
Table 58: Diagnostic Test - Lung Cancer - Product Status 58
Table 59: Diagnostic Test - Lung Cancer - Product Description 58
Table 60: Armune BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 59
Table 61: Diagnostic Test - Lung Cancer - Product Status 59
Table 62: Diagnostic Test - Lung Cancer - Product Description 59
Table 63: Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
Table 64: Lung Cancer Screening Test - Product Status 60
Table 65: Lung Cancer Screening Test - Product Description 60
Table 66: Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61
Table 67: TheraLink Assay - Non-Small Cell Lung Cancer - Product Status 61
Table 68: TheraLink Assay - Non-Small Cell Lung Cancer - Product Description 61
Table 69: BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 62
Table 70: BARD1 Lung Cancer Test - Product Status 62
Table 71: BARD1 Lung Cancer Test - Product Description 62
Table 72: Biocept Inc Pipeline Products & Ongoing Clinical Trials Overview 63
Table 73: Companion Diagnostic Target Selector Test - SCLC - Product Status 63
Table 74: Companion Diagnostic Target Selector Test - SCLC - Product Description 63
Table 75: MicroRNA Test - Lung Cancer - Product Status 64
Table 76: MicroRNA Test - Lung Cancer - Product Description 64
Table 77: BioChain Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 65
Table 78: Blood - Based Lung Cancer Test - Product Status 65
Table 79: Blood - Based Lung Cancer Test - Product Description 65
Table 80: BioChain Institute Inc - Ongoing Clinical Trials Overview 66
Table 81: Blood - Based Lung Cancer Test - BioChain Clinical Trial on novel, blood-based lung cancer test 67
Table 82: Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 68
Table 83: PD-L1 Blood Based Diagnostic Test - Product Status 68
Table 84: PD-L1 Blood Based Diagnostic Test - Product Description 68
Table 85: TAm-Seq NGS Lung Cancer Test - Product Status 69
Table 86: TAm-Seq NGS Lung Cancer Test - Product Description 69
Table 87: VeriStrat - NSCLC - Product Status 69
Table 88: VeriStrat - NSCLC - Product Description 70
Table 89: Biological Dynamics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
Table 90: OncoState Lung Assay - Product Status 71
Table 91: OncoState Lung Assay - Product Description 71
Table 92: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 72
Table 93: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Status 72
Table 94: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Description 72
Table 95: BioMark Diagnostics Inc. - Ongoing Clinical Trials Overview 73
Table 96: Metabolomics-based Diagnostic Assay - Lung Cancer - Clinical Trial with Patented Non-invasive, Urine-based Assay to Measure Response to Treatment for Lung Cancer 74
Table 97: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 75
Table 98: Ex Vivo Biomarker Test - Lung Cancer - Product Status 75
Table 99: Ex Vivo Biomarker Test - Lung Cancer - Product Description 75
Table 100: PathMAP NSCLC - Product Status 76
Table 101: PathMAP NSCLC - Product Description 76
Table 102: BioNTech AG Pipeline Products & Ongoing Clinical Trials Overview 77
Table 103: Lung Cancer Screening Test - Product Status 77
Table 104: Lung Cancer Screening Test - Product Description 77
Table 105: BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 78
Table 106: QuantiPlasma Antibody Based Test - Lung Cancer - Product Status 78
Table 107: QuantiPlasma Antibody Based Test - Lung Cancer - Product Description 78
Table 108: Cancer Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 79
Table 109: Companion Diagnostic Test - Tavocept - Product Status 79
Table 110: Companion Diagnostic Test - Tavocept - Product Description 79
Table 111: Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 80
Table 112: MCM Test - Lung Cancer - Product Status 80
Table 113: MCM Test - Lung Cancer - Product Description 80
Table 114: Cangen Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 81
Table 115: Diagnostic Test - Early Stage Lung Cancer - Product Status 81
Table 116: Diagnostic Test - Early Stage Lung Cancer - Product Description 81
Table 117: CDI Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 82
Table 118: Diagnostic Test - Lung Cancer - Product Status 82
Table 119: Diagnostic Test - Lung Cancer - Product Description 82
Table 120: Cellanyx Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 83
Table 121: Cellanyx Test - Lung Cancer - Product Status 83
Table 122: Cellanyx Test - Lung Cancer - Product Description 83
Table 123: CellMax Life Pipeline Products & Ongoing Clinical Trials Overview 84
Table 124: Cellmax - Lung Cancer - Product Status 84
Table 125: Cellmax - Lung Cancer - Product Description 84
Table 126: CeMines, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 85
Table 127: CellCorrect LAb Test For Lung Cancer - Product Status 85
Table 128: CellCorrect LAb Test For Lung Cancer - Product Description 85
Table 129: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 86
Table 130: Xpert Lung CA Early Detection Test - Product Status 86
Table 131: Xpert Lung CA Early Detection Test - Product Description 86
Table 132: Xpert OncoScreen Lung Cancer Assay - Product Status 87
Table 133: Xpert OncoScreen Lung Cancer Assay - Product Description 87
Table 134: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 88
Table 135: Nanotrap Lung Cancer Biomarker Test - Product Status 88
Table 136: Nanotrap Lung Cancer Biomarker Test - Product Description 88
Table 137: Cernostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 89
Table 138: TissueCypher Lung Cancer Test - Product Status 89
Table 139: TissueCypher Lung Cancer Test - Product Description 89
Table 140: ChemImage Corp Pipeline Products & Ongoing Clinical Trials Overview 90
Table 141: Prognostic Test - Lung Cancer - Product Status 90
Table 142: Prognostic Test - Lung Cancer - Product Description 90
Table 143: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 91
Table 144: Collagen XXIII Biomarker Assay - NSCLC - Product Status 91
Table 145: Collagen XXIII Biomarker Assay - NSCLC - Product Description 91
Table 146: Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview 92
Table 147: ALK PCR Test - NSCLC - Product Status 92
Table 148: ALK PCR Test - NSCLC - Product Description 92
Table 149: PulmoTax - Product Status 93
Table 150: PulmoTax - Product Description 93
Table 151: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 94
Table 152: Lung Cancer Diagnostic Panel - Product Status 94
Table 153: Lung Cancer Diagnostic Panel - Product Description 94
Table 154: DiagnoCure Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 95
Table 155: Diagnostic Test - Lung Cancer - Product Status 95
Table 156: Diagnostic Test - Lung Cancer - Product Description 95
Table 157: EDP Biotech Corporation Pipeline Products & Ongoing Clinical Trials Overview 96
Table 158: PulmoMarker Test - Product Status 96
Table 159: PulmoMarker Test - Product Description 96
Table 160: Emory University Pipeline Products & Ongoing Clinical Trials Overview 97
Table 161: Biomarker Assay - Small Cell Lung Cancer - Product Status 97
Table 162: Biomarker Assay - Small Cell Lung Cancer - Product Description 97
Table 163: Epic Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 98
Table 164: PD-L1 Blood Test - Product Status 98
Table 165: PD-L1 Blood Test - Product Description 98
Table 166: Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 99
Table 167: Epi proLung BL 1.0 - Blood Plasma - Product Status 99

1.2 List of Figures
Figure 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 25
Figure 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 26
Figure 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 27
Figure 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 28
Figure 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 29
Filed in: In Vitro Diagnostic, Medical Device
Publisher : GlobalData